Výsledky vyhledávání - "Maud Jonnaert"

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study

Autor: Dong Wan Kim, Santiago Ponce Aix, Takashi Seto, Chun Pan, Gregory J. Riely, Lecia V. Sequist, Maud Jonnaert, Enriqueta Felip, Juergen Wolf, Jinnie Ko, Susan Moody, James Chih-Hsin Yang, Eugene Y. Tan, Natasha B. Leighl, Daniel Shao-Weng Tan

Publikováno v: The Lancet. Respiratory medicine. 8(6)

Summary Background Resistance to first-generation and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is mediated by the emergence of the Thr790Met mutation in 50–60% of treated patients with non-small-ce

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fecee5f096049134c7c231dc18f56ce9
https://pubmed.ncbi.nlm.nih.gov/31954623

Zobrazit plný text záznamu

890MO Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL

Autor: C. Bachier, Eleni Tholouli, Y. Zhang, Martin Pule, David Irvine, Robert T. Chen, N. Bartlet, K. Ardesha, Wendy Osborne, Muhammad Al-Hajj, Maria A V Marzolini, Nushmia Z. Khokhar, Vijay G R Peddareddigari, Simon Thomas, Aravind Ramakrishnan, Maud Jonnaert, P. McSweeney

Publikováno v: Annals of Oncology. 31:S651

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c1179a57859880720997850d9dd37516
https://doi.org/10.1016/j.annonc.2020.08.008

Zobrazit plný text záznamu

Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL

Autor: Martin Pule, Carlos R. Bachier, Wendy Osborne, Vijay G R Peddareddigari, David Irvine, Kirit M. Ardeshna, Nushmia Z. Khokhar, Maud Jonnaert, Simon Thomas, Aravind Ramakrishnan, Michael Zhang, Maria A V Marzolini, Eleni Tholouli, Peter A. McSweeney, Robert W. Chen, Muhammad Al-Hajj

Publikováno v: Journal of Clinical Oncology. 38:8001-8001

8001 Background: CD19 directed CAR T cells are effective in patients with r/r DLBCL, however relapses due to CD19 loss or PDL1 upregulation are common. In this study, we evaluate the safety and efficacy of AUTO3, a CAR T targeting CD19/22 with limite

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7b256a8b41befe69364d39614df77635
https://doi.org/10.1200/jco.2020.38.15_suppl.8001

Zobrazit plný text záznamu

Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

Autor: Vijay G R Peddareddigari, Martin Pule, Muhammad Al-Hajj, Robert T. Chen, Nushmia Z. Khokhar, Maria A V Marzolini, Simon Thomas, Kirit M. Ardeshna, Wendy Osborne, Jane Norman, Maud Jonnaert, Jim Faulkner, Ekaterini Kotsopoulou

Publikováno v: Blood. 134:246-246

Introduction: CD 19 CAR T cell therapies have shown significant activity in patients with r/r DLBCL, however relapses due to CD19 loss or PDL1 upregulation are common. In this study, we are evaluating the safety and efficacy of AUTO3, a CAR T cell th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::880c4fa04a72aea9f9ae4d37fe3fa0dd
https://doi.org/10.1182/blood-2019-122724

Zobrazit plný text záznamu

Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC)

Autor: Daniel Shao-Weng Tan, Susan Moody, Juergen Wolf, Maud Jonnaert, Enriqueta Felip, Natasha B. Leighl, Sinead Dolan, Lecia V. Sequist, Chun Pan, James Chih-Hsin Yang, Dong Wan Kim, Takashi Seto, Gregory J. Riely, Jordi Barretina, Santiago Ponce Aix

Publikováno v: Journal of Clinical Oncology. 35:11506-11506

11506 Background: Up to 60% of patients (pts) with NSCLC harboring an activating EGFR mutation (mut) and treated with a 1st generation EGFR TKI develop a secondary gatekeeper T790M mut. EGF816 is an irreversible EGFR TKI that is highly potent against

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ff7b5516d0d706184d0f7d19f2562239
https://doi.org/10.1200/jco.2017.35.15_suppl.11506

Zobrazit plný text záznamu

Uterine Wnt/β-catenin signaling is required for implantation

Autor: Maud Jonnaert, Othman A. Mohamed, Cassandre Labelle-Dumais, Hugh J. Clarke, Kazuki Kuroda, Daniel Dufort

Successful implantation relies on precisely orchestrated and reciprocal signaling between the implanting blastocyst and the receptive uterus. We have examined the role of the Wnt/β-catenin signaling pathway during the process of implantation and dem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eee1b62b4965e76750a0bad7d331a0ca
https://europepmc.org/articles/PMC1150820/

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání